The Trump administration did away with a Biden-era proposal to allow Medicare to start paying for weight loss drugs such as ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Eli Lilly & Co.’s shares fell Monday morning after the Trump administration spiked a plan late last week to pay for obesity drugs for Medicare patients.

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

As demand soared for weight-loss drugs, price signals worked.

Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...